The next time you visit one of your favorite websites, you could be sending a signal to marketers about your consumer preferences, notes legal columnist Deb Wilcox. In this edition of IP Online, she examines the privacy concerns over behavioral advertising technology, and notes that...
Marshfield, Wisconsin may seem an unlikely place for medical breakthroughs, but last week's announcement of a new collaboration by Wisconsin's four leading medical research institutions could well lead to advances in personalized medicine, according to Inside Wisconsin columnist Tom Still. The announcement of the Wisconsin...
Wisconsin invests heavily in educating its young people and offers a high quality of life, which is why it's so frustrating to see them lured away to other states upon their college graduation. In this edition of Inside Wisconsin, columnist Tom Still chronicles what's being...
Finally, some good news about e-discovery requests. As Digital Lex columnist and attorney Mark Foley explains, a new rule pertaining to the inadvertent disclosure of materials subject to attorney-client privilege addresses some of the shortcomings of a previous rule. However, this does not absolve IT...
It may sound like lunacy to view the current economic crisis as an opportunity, but columnist and innovation expert Tom Koulopoulos thinks it could well be a turning point if we learn the right lessons. In this edition of the Innovation Zone, he offers some...
“Software is too serious a matter to be entrusted to IT,” according to columnist Robert Merrill, as he paraphrases Georges Clemenceau, prime minister of France during World War I. In this WTN guest column, Merrill's advice to software-intensive businesses is that the benefits of software...
There may not be any human embryonic stem cell-derived therapies or cures, but that's understandable, according to columnist Tom Still. In this edition of Inside Wisconsin, he notes that the average drug takes 12 to 15 years to reach the market, so the lack of...
Columnist Steven S. Clark, commenting on the controversial financial rescue plan, says we've got Congressmen and women right where we want them - running for re-election after voting to pass an unpopular bailout bill. In this edition of Biotech Takes, Clark also wonders what the...
To many, this question is a no-brainer, one answered with an emphatic yes, and columnist Michael Rosen is not about to argue. In this edition of Yer Biotech Blues, Rosen talks about the some of the changes proposed by former House Speaker Newt Gingrich to...
In this political season, there will be a lot of claims about the benefits of embryonic stem cell research, but a little bit of perspective is in oder as politicians try to get themselves elected. That perspective was provided during the recent World Stem Cell...